These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19581391)

  • 1. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models.
    Daher LJ; Demanga CG; Prieur E; Pérignon JL; Bouharoun-Tayoun H; Druilhe P
    Infect Immun; 2010 Jan; 78(1):477-85. PubMed ID: 19581391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.
    Demanga CG; Daher LJ; Prieur E; Blanc C; Pérignon JL; Bouharoun-Tayoun H; Druilhe P
    Infect Immun; 2010 Jan; 78(1):486-94. PubMed ID: 19884337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
    Bang G; Prieur E; Roussilhon C; Druilhe P
    PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
    Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
    Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum.
    Singh S; Soe S; Weisman S; Barnwell JW; Pérignon JL; Druilhe P
    PLoS One; 2009; 4(4):e5410. PubMed ID: 19404387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.
    Singh S; Soe S; Mejia JP; Roussilhon C; Theisen M; Corradin G; Druilhe P
    J Infect Dis; 2004 Sep; 190(5):1010-8. PubMed ID: 15295710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection.
    Deshmukh A; Chourasia BK; Mehrotra S; Kana IH; Paul G; Panda A; Kaur I; Singh SK; Rathore S; Das A; Gupta P; Kalamuddin M; Gakhar SK; Mohmmed A; Theisen M; Malhotra P
    Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29760216
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.
    Polley SD; Tetteh KK; Lloyd JM; Akpogheneta OJ; Greenwood BM; Bojang KA; Conway DJ
    J Infect Dis; 2007 Jan; 195(2):279-87. PubMed ID: 17191173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.
    Audran R; Cachat M; Lurati F; Soe S; Leroy O; Corradin G; Druilhe P; Spertini F
    Infect Immun; 2005 Dec; 73(12):8017-26. PubMed ID: 16299295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M; Soe S; Brunstedt K; Follmann F; Bredmose L; Israelsen H; Madsen SM; Druilhe P
    Vaccine; 2004 Mar; 22(9-10):1188-98. PubMed ID: 15003647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.
    Joshi MB; Gam AA; Boykins RA; Kumar S; Sacci J; Hoffman SL; Nakhasi HL; Kenney RT
    Infect Immun; 2001 Aug; 69(8):4884-90. PubMed ID: 11447164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.
    Imam M; Devi YS; Verma AK; Chauhan VS
    Clin Vaccine Immunol; 2011 Aug; 18(8):1221-8. PubMed ID: 21632889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion of an Optimized
    Eacret JS; Parzych EM; Gonzales DM; Burns JM
    J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984
    [No Abstract]   [Full Text] [Related]  

  • 18. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.
    Theisen M; Dodoo D; Toure-Balde A; Soe S; Corradin G; Koram KK; Kurtzhals JA; Hviid L; Theander T; Akanmori B; Ndiaye M; Druilhe P
    Infect Immun; 2001 Sep; 69(9):5223-9. PubMed ID: 11500389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM; Miura K; Long CA; Burns JM
    PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.